Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer
Suresh S. Ramalingam(Emory University), Fadlo R. Khuri(American University of Beirut Medical Center), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Gabriel Sica(Emory University), Scott A. Kono(Emory University), Janakiraman Subramanian(Skin Cancer Foundation), Nabil F. Saba(Emory University), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), R. Donald Harvey(Emory University), Ramaswamy Govindan(Washington University in St. Louis), Haian Fu(Emory University), Carmen M. Klass(Northwest Behavioral Medicine), Shi-yong R. Sun(Emory University), Dong M. Shin(Emory University), Anthony A. Gal(Emory University), Madhusmita Behera(National Institutes of Health)
Cited by 39
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k